Merrill Shum, MD

Kidney stone procedures are among the most common interventions in urology, yet complete stone clearance can be challenging with today’s tools. Ventaris Surgical is developing a next-generation ureteroscopic system designed to streamline key steps in the procedure and support surgeons in achieving thorough stone clearance.

Revolutionary breast cancer risk assessment and early detection solution delivering immediate, accurate results for women of all ages and all ethnicities.

The open-source health research cloud for ML/AI. Were bringing the brightest researchers and model developers together with clinicians and life sciences companies to accelerate the future of healthcare.

Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient-specific biomarkers of response to novel and existing cancer therapies. Our unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding most accurate composite tumour models. Using Concr’s cloud native platform – FarrSight® – researchers can make advanced predictions about biomarkers by leveraging Concr’s unique technology, and perform standard bioinformatics analyses directly. Concr is headquartered in London, with a wholly-owned subsidiary in Brisbane, Australia. The company is a venture capital-backed enterprise, with investors including the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Cambridge Angels, Deep Science Ventures and SyndicateRoom.

At Oncovery, we’re rethinking care for cancer survivors. We believe in a world where survivorship isn’t just surviving—it’s thriving. Our comprehensive, integrated survivorship care model is designed to help you live well beyond a cancer diagnosis.

Autonomous restaurant solution serving gourmet ramen in 45 seconds. Using the highest fresh locally sourced ingredients, delicately prepared in USDA facility, never instant and no preservatives. No down time! Our machines is open 24 hours a day which makes us the perfect solution for off hour dining and meal solutions for those without food options readily available. Currently you can find Yo-Kai in office settings, large factories, amusement parks, universities, hospitals, retail shopping centers, and soon international airports, ski resorts.

Mon Ami Real Estate is a value-driven investor-operator focused on the overlooked middle market: sub-$30M Class B/C retail & industrial across the U.S. Over the past 15 years, weve developed an investment strategy focused on acquiring properties with intrinsic value, enhancing performance post-acquisition, and delivering attractive risk-adjusted returns for our investors. We win where complexity and timing narrow the buyer pool—buying at a discount, closing with speed and certainty, and executing in-house.

Kidney stone procedures are among the most common interventions in urology, yet complete stone clearance can be challenging with today’s tools. Ventaris Surgical is developing a next-generation ureteroscopic system designed to streamline key steps in the procedure and support surgeons in achieving thorough stone clearance.

Oncology Ventures invests in commercially-validated start-ups transforming the future of cancer care. Investments are listed here: https://www.oncology.ventures/portfoliocompanies Join our 16k+ monthly readers of oncology insights (+ comedy) here: https://oncologyventures.substack.com/

Revolutionary breast cancer risk assessment and early detection solution delivering immediate, accurate results for women of all ages and all ethnicities.

The open-source health research cloud for ML/AI. Were bringing the brightest researchers and model developers together with clinicians and life sciences companies to accelerate the future of healthcare.

Concr is a mission-driven techbio company that uses established methods from astrophysics to accurately predict patient-specific biomarkers of response to novel and existing cancer therapies. Our unique approach allows iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, removing the need for ‘big data’ and yielding most accurate composite tumour models. Using Concr’s cloud native platform – FarrSight® – researchers can make advanced predictions about biomarkers by leveraging Concr’s unique technology, and perform standard bioinformatics analyses directly. Concr is headquartered in London, with a wholly-owned subsidiary in Brisbane, Australia. The company is a venture capital-backed enterprise, with investors including the University of Cambridge Enterprise, R42 Group, Oncology Ventures, Cambridge Angels, Deep Science Ventures and SyndicateRoom.